# Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line

> **NCT02187042** · — · COMPLETED · sponsor: **Pfizer** · enrollment: 70 (actual)

## Conditions studied

- Metastatic/Advanced Renal Cell Carcinoma

## Interventions

- **OTHER:** Best supportive care
- **OTHER:** call center

## Key facts

- **NCT ID:** NCT02187042
- **Lead sponsor:** Pfizer
- **Sponsor class:** INDUSTRY
- **Phase:** —
- **Study type:** OBSERVATIONAL
- **Status:** COMPLETED
- **Start date:** 2015-10-07
- **Primary completion:** 2018-07-25
- **Final completion:** 2018-07-25
- **Target enrollment:** 70 (ACTUAL)
- **Last updated:** 2019-10-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02187042

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02187042, "Evaluation Of The Impact Of A Call Center In Management Of Metastatic And/Or Advanced Renal Cell Carcinoma Patients Treated With Sunitinib (Sutent) In First Line". Retrieved via AI Analytics 2026-05-28 from https://api.ai-analytics.org/clinical/NCT02187042. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*